NOV 28, 2016 11:07 AM PST

Cancer Drug May be Repurposed to Treat Muscular Dystrophy

WRITTEN BY: Xuan Pham
A cancer drug that’s approved for the treatment of kidney cancer may also be effective against a form of muscular dystrophy.
 

Sunitinib is a small-molecule drug that inhibits receptor tyrosine kinases (RTK). It was approved by the FDA for the treatment of renal cell carcinoma and a form of gastrointestinal tumor in 2006. Now, researchers at the King’s College London say the mechanism behind this drug may also act to improve muscle strength in patients with facioscapulohumeral dystrophy (FSHD).
 
FSHD is a genetically inherited form of muscular dystrophy that primarily affects the muscles around the face, shoulders, and upper arms. Patients with this condition experience progressive muscle wasting that starts in early childhood. The muscle weakness can severely impair mobility, speaking, and even breathing.
 
"Muscle dystrophies are an untreatable collection of diseases that result in progressive loss of mobility and often premature death, and affect millions of people worldwide,” said Robert Knight, Principal Investigator at the Division of Craniofacial Development and Stem Cell Biology at King’s College London’s Dental Institute, and the study’s co-lead author.
 
In studying muscle biology, researchers noted that a receptor tyrosine kinase Rearranged during transfection (RET) seemed to be upregulated in muscle stem cells that express the DUX4 protein. In FSHD, the genomic region controlling DUX4 appears to be abnormally activated (due to hypomethylation). This, in turn, overstimulates the production and activity of DUX4, which seems to contribute to the muscle weakness characteristic of FSHD.
 
Could an RTK inhibitor reverse this effect? This was the researcher’s main hypothesis, and they tested it first by confirming that overexpression of DUX4 in mice led to upregulation of RET. Furthermore, administration of sunitinib, an RTK inhibitor, suppressed RET activity and reduced damage to muscle cells.
 

“Specifically, blocking DUX4-mediated RET signaling increases myogenic differentiation, giving further insight into the molecular pathology of DUX4 and highlighting RET signaling as potential drug target," the authors explain.
 
The drug shows promise in improving muscle strength for patients afflicted with FSHD. And since the drug is already approved, repurposing it for the treatment of FSHD may take much less time, assuming further studies also find the same promising results.
 
“The discovery that an approved anticancer treatment may prove useful for enhancing the ability of stem cells to repair muscle in a type of muscle dystrophy affecting face and shoulder muscles offers a new route for putative therapies for many patients,” said Knight.

Additional sources: King's College London press release, MNT
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 06, 2020
Drug Discovery & Development
New Immunotherapy Drug Effective Against Lung Cancer
OCT 06, 2020
New Immunotherapy Drug Effective Against Lung Cancer
A new study has confirmed that Tecentriq, an immunotherapy drug, improves survival rates among those with newly diagnose ...
OCT 08, 2020
Immunology
Immuno Metabolic Complexity and Modulating Metabolites
OCT 08, 2020
Immuno Metabolic Complexity and Modulating Metabolites
Immunometabolism is a relatively new subspecialty of immunology as we’ve begun to unravel the complex metabolic re ...
OCT 08, 2020
Cancer
Oral cancer pain levels indicate metastasis
OCT 08, 2020
Oral cancer pain levels indicate metastasis
A new study from NYU College of Dentistry researchers provides insight as to why patients with metastatic oral cancer ex ...
OCT 13, 2020
Immunology
Early Tips For Cell & Gene Therapy Regulatory Compliance
OCT 13, 2020
Early Tips For Cell & Gene Therapy Regulatory Compliance
Cell and gene therapies hold great promise for improved health outcomes. Now is the time to advance life-saving research ...
OCT 14, 2020
Cancer
Research suggests statins could reduce the risk of cancer
OCT 14, 2020
Research suggests statins could reduce the risk of cancer
New research published in the journal eLife provides evidence that statins, the common cholesterol-lowering drugs, could ...
NOV 23, 2020
Cancer
Platelets May Protect Cancer Against PD-1 Therapies
NOV 23, 2020
Platelets May Protect Cancer Against PD-1 Therapies
One of cancer’s greatest tools is its ability to manipulate the immune system. Many cancer therapies have arisen t ...
Loading Comments...